The benefits remain out of reach for too many and the research is concentrated in high income countries.
In May 2026, health ministers from across the world gathered at the Seventy-ninth World Health Assembly and endorsed a resolution committing the global community to precision medicine — the practice of tailoring care to individual patients through genomic and clinical data — not as a privilege of wealthy nations, but as a shared inheritance of humanity. The vote acknowledged a quiet injustice already underway: that the most transformative advances in personalized medicine are being built on data that excludes the majority of the world's people. The resolution asks member states to build the infrastructure, train the workforce, and govern these tools with equity at the center, so that the next generation of medical innovation does not simply widen the distance between those who have and those who do not.
- Precision medicine is already saving lives — matching cancer therapies to tumor mutations, catching rare diseases in newborns — but almost entirely within wealthy nations, leaving the rest of the world behind.
- Low- and middle-income countries are largely absent from the genomic databases driving this revolution, meaning treatments developed without their data may simply not work for their populations.
- The World Health Assembly's endorsed resolution creates a formal mandate for WHO and member states to close this gap through infrastructure investment, workforce training, and inclusive research design.
- WHO will develop a Global Strategy and a country maturity model, giving nations a realistic, context-sensitive roadmap to assess their own capacity and chart a path toward equitable integration.
- The harder challenge now is political will — building trust in systems that have historically exploited vulnerable communities, sharing data across borders, and ensuring that genetic contributions flow benefits back to the people who gave them.
In May 2026, health ministers from around the world voted at the Seventy-ninth World Health Assembly to endorse a resolution on precision medicine — the science of tailoring prevention, diagnosis, and treatment to individual patients using their genetic and clinical data. The vote was not about a new drug. It was about a commitment to ensure that this already-transforming field reaches everyone, not just those born in wealthy countries.
Precision medicine is working. Oncologists are matching patients to therapies based on tumor mutations. Newborns are being screened for rare diseases before symptoms appear. But nearly all of this innovation is concentrated in high-income nations, built on datasets that largely exclude populations from Africa, Southeast Asia, Latin America, and the Pacific. The gap is widening, and the treatments being developed may not work as well — or at all — for those left out of the research.
The resolution confronts this directly. Member states committed to building national infrastructure, training specialized workforces, strengthening regulation, and ensuring genomic databases reflect the full diversity of humanity. WHO will map existing frameworks, convene global consultations, and develop both a Global Strategy on Precision Medicine and a maturity model allowing countries to assess their capacity and chart realistic paths forward.
Dr. Meg Doherty, WHO's Director of Science for Health, was direct: precision medicine is not a future promise — it is already transforming lives, but those transformations are concentrated in a handful of nations. Dr. Sylvie Briand, WHO's Chief Scientist, added that its true potential is only realized when united with people-centered care.
The framework now exists. The commitment is on record. What follows depends on whether member states translate political will into the harder work of building systems, training geneticists and counselors where those professions barely exist, and earning trust in communities that have historically been exploited in the name of research — not as afterthoughts, but as the center of the work from the start.
In May 2026, health ministers from around the world gathered at the Seventy-ninth World Health Assembly and voted to endorse a resolution that could reshape how medicine is practiced globally. The vote was not about a new drug or a breakthrough discovery. It was about a commitment to bring precision medicine—the practice of tailoring prevention, diagnosis, and treatment to individual patients using their genetic, molecular, and clinical data—into health systems everywhere, with a deliberate focus on making sure the poorest and most vulnerable populations benefit first.
Precision medicine is already working. Doctors are using genomic data to catch rare diseases in newborns before symptoms appear. Oncologists are matching cancer patients to therapies based on the specific mutations in their tumors. Mental health providers are beginning to understand why certain medications work for some people and not others. The technology exists. The science is real. But here is the problem: nearly all of this innovation is happening in wealthy countries. Researchers in high-income nations are building the databases, running the trials, and publishing the findings. Populations in low- and middle-income countries are largely absent from these datasets, which means the treatments being developed may not work as well for them, or may not work at all. The gap is widening, not closing.
The resolution passed at the assembly acknowledges this directly. It commits member states to build the infrastructure, train the workforce, and create the governance structures needed to integrate precision medicine safely and ethically into their own health systems. This means developing national policies, strengthening regulation, ensuring that genomic databases include diverse populations, and making sure these tools are affordable. It means research that includes people from Africa, Southeast Asia, Latin America, and the Pacific—not as afterthoughts, but as central to the work from the start.
Dr. Meg Doherty, the WHO's Director of Science for Health, framed the moment plainly: precision medicine is not a future promise, she said. It is already transforming lives. But those transformations are concentrated in a handful of wealthy nations. The resolution gives the WHO and health ministries a mandate to change that. The organization will begin by mapping all existing guidance and frameworks, then convene global consultations to understand what each country needs. It will develop a Global Strategy on Precision Medicine and create a maturity model—a tool that allows countries to assess their own capacity and chart a realistic path forward based on their resources and context.
The work ahead is substantial. It requires not just money but political will, technical expertise, and a willingness to share data across borders while protecting privacy and ensuring that benefits flow back to the communities that contribute their genetic information. It requires training geneticists, bioinformaticians, and genetic counselors in countries where those professions barely exist. It requires building trust in systems that have historically exploited vulnerable populations in the name of research.
Dr. Sylvie Briand, the WHO's Chief Scientist, offered a different angle: precision medicine, she said, has the potential to transform lives when it is united with people-centered care. The resolution ensures that the advances being made in laboratories and hospitals in wealthy countries will be directed toward a shared goal—health for all, not health for some. What happens next depends on whether member states follow through. The WHO has provided the framework. The commitment is on record. Now comes the harder part: the actual work of building systems, training people, and ensuring that the next generation of medical innovation reaches everyone.
Notable Quotes
Precision medicine is already transforming lives across the world, but its benefits remain out of reach for too many and the research driving progress is concentrated in high-income countries.— Dr. Meg Doherty, WHO Director of Science for Health
By uniting people-centered healthcare with innovation, precision medicine has the potential to transform lives and ensure those advances serve the shared goal of health for all.— Dr. Sylvie Briand, WHO Chief Scientist
The Hearth Conversation Another angle on the story
Why does it matter that low- and middle-income countries are underrepresented in precision medicine research?
Because the treatments being developed are optimized for the populations in the studies. If your genetic data isn't in the database, the algorithm doesn't know how your body will respond. You become an outlier, or worse, you don't get treated at all.
But isn't precision medicine expensive? How do countries with limited budgets implement this?
That's exactly why the resolution emphasizes affordability and context-appropriate implementation. A country doesn't need to build everything at once. The maturity model lets them start where they are—maybe with infant screening, maybe with a regional genomic database—and scale up as capacity grows.
What's the risk if this doesn't work?
Health disparities widen. The wealthy get personalized, targeted care. Everyone else gets the old playbook. You end up with two tiers of medicine, and the gap between them keeps growing.
Who actually has to do the work—WHO or the countries themselves?
Both. WHO provides the strategy, the tools, the technical support. But member states have to build the infrastructure, train the people, and make the political choices about how to integrate this into their health systems. It's a partnership, but the responsibility is shared.
Is there a timeline?
The resolution doesn't specify one. WHO is starting immediately with mapping and consultations. But real implementation—building databases, training workforces, changing how hospitals operate—that's a years-long effort. This is a commitment, not a quick fix.